Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,549 INR | +1.08% | +8.58% | -1.10% |
05-14 | Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505 | MT |
05-13 | Dr. Lal Pathlabs' Fiscal Q4 Consolidated Net Profit Rises; Share Up 6% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The opinion of analysts covering the stock has improved over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 59.72 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.10% | 2.51B | B- | ||
-16.99% | 8.67B | B+ | ||
+65.23% | 4.25B | C+ | ||
-10.68% | 2.47B | - | ||
-41.76% | 2.25B | B- | ||
-8.53% | 1.91B | C- | ||
-19.29% | 1.56B | A- | ||
-39.61% | 1.19B | C+ | ||
+9.54% | 1.15B | B+ | ||
+14.87% | 964M | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LALPATHLAB Stock
- Ratings Dr. Lal PathLabs Limited